Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer

Samsung Medical Center

Status and phase

Enrolling

Phase 3

Conditions

Endometrial Cancer Stage I

Treatments

Drug: Metformin

Study type

Interventional

Funder types

Other

Identifiers

NCT04792749

MetforminEndometrialCancer

Details and patient eligibility

About

The purpose of the study is to investigate the effects of metformin in addition to the conventional progestin therapy in the fertility-sparing treatment of early stage endometrial cancer.

Enrollment

77 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Endometrial cancer radiologic International Federation of Obstetrics and Gynecology (FIGO) stage IA patients
Endometrioid endometrial cancer patients
FIGO cellular differentiation grade 1 patients
Patients who wish to preserve fertility
Patients who understand that the recommended treatment of endometrial cancer is surgical treatment even in early stages, but still wish to preserve fertility and avoid surgical treatment
Patients who have good performance status (Eastern Cooperation Oncology Group (ECOG) performance score equal to or greater than 3)
Patients who are not contraindicated to the progestin therapy
Patients who are not contraindicated to the use of metformin

Exclusion criteria

Patients who have already received chemotherapeutic or radiotherapeutic treatments for endometrial cancer
Patients whose disease is already advanced and not indicated for fertility-sparing treatment
Patients whose tumor cellular differentiation grade is greater than FIGO grade 1